A single injection every 3 months of a novel drug that targets the lipid metabolism enzyme ANGPTL3 resulted in substantial reductions in LDL cholesterol in patients with HoFH in the phase 2 GATEWAY trial.
Children and adolescents with homozygous familial hypercholesterolemia could benefit from lomitapide therapy, suggests a trial, although safety concerns and upcoming novel drugs question its place.
A simple-to-obtain measure of insulin resistance can stratify cardiac risk in patients who have undergone coronary artery bypass graft surgery to better guide follow-up care.
Major depressive disorder is linked to disruptions in energy and lipid metabolism, possibly caused by the interplay of the gut microbiome and blood metabolome.
Metabolic syndrome that develops in middle age had a greater association with osteoarthritis knee symptoms and pain than metabolic syndrome that resolved or persistent metabolic syndrome in a recent study.